A Phase 2 interventional study of BI 1015550 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 75 sites in 22 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-11-01.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 7 in phase 2, and was the 21st registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Belgium, Finland and 6 more countries
Ages 40+
By country, each count listing its studies:
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 109 across the 18 interventional studies, 212 across the 16 observational. Of the 31 that completed or were terminated, 26 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
2 of the studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07036523Boehringer IngelheimA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | 2027-03-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
The purpose of the study is to find out whether a medicine called BI 1015550 can slow down the worsening of lung function. Participants are in the study for about 4 months. During this time, they visit the study site about 7 times. At the beginning, they visit the study site every 2 weeks.
After 1 month of treatment, they visit the study site every 4 weeks.
The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The participants take BI 1015550 or placebo tablets twice a day.
The participants have lung function tests at study visits. The results of the lung function tests are compared between the BI 1015550 group and the placebo group. The doctors also regularly check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis:
IPF based on 2018 ATS/ERS/JRS/ALAT Guideline as confirmed by the investigator based on chest High Resolution Computed Tomography Scan (HRCT) scan taken within 12 months of Visit 1 and if available surgical lung .
and
Usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with the clinical diagnosis of IPF, as confirmed by central review prior to Visit 2*
Stable for at least 8 weeks prior to Visit 1. Patients have to be either :
[*stable therapy is defined as the individually and general tolerated regimen of either pirfenidone or nintedanib]
Exclusion Criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
Drug: Placebo
Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
Drug: BI 1015550
Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Drug: Placebo
Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
Drug: BI 1015550
18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks
The change from baseline in Forced vital capacity (FVC) at 12 weeks. Data were analysed with a restricted maximum likelihood (REML)-based approach using a mixed model with repeated measures (MMRM). The analysis included the fixed, categorical effect of treatment at each visit, and the fixed, continuous effects of baseline FVC at each visit. Visit was treated as the repeated measure, with an unstructured covariance structure used to model the within-patient measurements.
Time frame: Baseline (day 1) and week 12.
The Number of Patients With Treatment Emergent Adverse Event
The number of patients with any adverse event during the on-treatment period.
Time frame: From the start of treatment till the end of treatment + 7 days residual effect period, an average of 87.4 days.
This was a trial with a randomised, placebo-controlled, double-blind, parallel-group design over 12 weeks, including a screening period of up to 44 days, a 12-week treatment period, and a 1-week follow-up period in patients with idiopathic pulmonary fibrosis (IPF) stratified by baseline antifibrotic treatment (Non-AF stratum: patients not on antifibrotic treatment at baseline; AF stratum: stable antifibrotic treatment with nintedanib or pirfenidone at baseline).
| Milestone | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline |
|---|---|---|---|---|
| Started | 25 | 49 | 25 | 48 |
| Completed | 25 | 39 | 25 | 43 |
| Not completed | 0 | 10 | 0 | 5 |
| Withdrew: Adverse event | 0 | 10 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Poor-compliance | 0 | 0 | 0 | 1 |
The change from baseline in Forced vital capacity (FVC) at 12 weeks. Data were analysed with a restricted maximum likelihood (REML)-based approach using a mixed model with repeated measures (MMRM). The analysis included the fixed, categorical effect of treatment at each visit, and the fixed, continuous effects of baseline FVC at each visit. Visit was treated as the repeated measure, with an unstructured covariance structure used to model the within-patient measurements.
| Milliliter | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline |
|---|---|---|---|---|
| The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks | -77.70 (-124.87 to -30.53) | 2.72 (-33.46 to 38.89) | -95.62 (-157.13 to -34.10) | 6.10 (-39.67 to 51.88) |
The number of patients with any adverse event during the on-treatment period.
| Participants | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline |
|---|---|---|---|---|
| The Number of Patients With Treatment Emergent Adverse Event | 5 | 18 | 5 | 9 |
Collected over From the start of treatment till the end of treatment + 7 days residual effect period, an average of 87.4 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Antifibrotics at Baseline | 0/25 (0%) | 0/25 (0%) | 10/25 (40%) |
| BI 1015550 - Antifibrotics at Baseline | 1/49 (2%) | 3/49 (6.1%) | 24/49 (49%) |
| Placebo - Non-antifibrotics at Baseline | 0/25 (0%) | 5/25 (20%) | 5/25 (20%) |
| BI 1015550 - Non-antifibrotics at Baseline | 1/48 (2.1%) | 3/48 (6.3%) | 18/48 (37.5%) |
| Event | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline |
|---|---|---|---|---|
| Condition aggravatedGeneral disorders | 0/25 | 2/49 | 0/25 | 0/48 |
| UrosepsisInfections and infestations | 0/25 | 0/49 | 1/25 | 0/48 |
| Wound infectionInfections and infestations | 0/25 | 0/49 | 1/25 | 0/48 |
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 0/25 | 0/49 | 1/25 | 0/48 |
| Transient ischaemic attackNervous system disorders | 0/25 | 0/49 | 1/25 | 0/48 |
| Dermatitis exfoliativeSkin and subcutaneous tissue disorders | 0/25 | 0/49 | 1/25 | 0/48 |
| Cardiac failure congestiveCardiac disorders | 0/25 | 0/49 | 0/25 | 1/48 |
| COVID-19 pneumoniaInfections and infestations | 0/25 | 0/49 | 0/25 | 1/48 |
| Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/49 | 0/25 | 1/48 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/25 | 0/49 | 0/25 | 1/48 |
| Event | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/25 | 15/49 | 2/25 | 8/48 |
| FatigueGeneral disorders | 3/25 | 1/49 | 1/25 | 2/48 |
| NasopharyngitisInfections and infestations | 0/25 | 4/49 | 0/25 | 0/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/25 | 4/49 | 1/25 | 3/48 |
| ConstipationGastrointestinal disorders | 2/25 | 1/49 | 0/25 | 1/48 |
| NauseaGastrointestinal disorders | 0/25 | 1/49 | 2/25 | 2/48 |
| RashSkin and subcutaneous tissue disorders | 2/25 | 0/49 | 0/25 | 0/48 |
| DyspepsiaGastrointestinal disorders | 1/25 | 2/49 | 0/25 | 3/48 |
| FlatulenceGastrointestinal disorders | 1/25 | 2/49 | 1/25 | 3/48 |
| AstheniaGeneral disorders | 0/25 | 1/49 | 0/25 | 3/48 |
Treated Set (TS): all patients who received at least one dose of trial drug.
| Age, Continuous(years) | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline | Total |
|---|---|---|---|---|---|
| Mean | 67.5 ± 10.7 | 69.3 ± 6.6 | 71.8 ± 9.3 | 69.9 ± 8.3 | 69.6 ± 8.4 |
| Sex: Female, Male(Participants) | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline | Total |
|---|---|---|---|---|---|
| Female | 7 | 5 | 8 | 14 | 34 |
| Male | 18 | 44 | 17 | 34 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 | 5 | 13 |
| Not Hispanic or Latino | 24 | 46 | 21 | 43 | 134 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 12 | 4 | 12 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 21 | 37 | 21 | 36 | 115 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Forced vital capacity (FVC)(Milliliter) | Placebo - Antifibrotics at Baseline | BI 1015550 - Antifibrotics at Baseline | Placebo - Non-antifibrotics at Baseline | BI 1015550 - Non-antifibrotics at Baseline | Total |
|---|---|---|---|---|---|
| Mean | 2690.000 ± 889.985 | 2875.551 ± 752.818 | 2864.920 ± 1015.104 | 2782.938 ± 835.104 | 2811.946 ± 845.625 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Jul 2020 to primary completion in Oct 2021, 14 months.
Results were first posted in Nov 2022, 1 year after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 14 months is below that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast
Idiopathic Pulmonary Fibrosis →